To review the impact of latanoprost/timolol fixed-dose combination (LTFC) on patient-reported outcomes (PROMs) and assess its efficacy and safety in glaucoma treatment, highlighting the significance of PROMs in improving patient care.
Approach:
Key Findings:
LTFC improves patient adherence due to simplified dosing regimens, with adherence rates increasing by X%.
Patients report higher satisfaction and quality of life after switching to LTFC, with satisfaction scores improving by Y points.
Adverse effects were minimal, with a high percentage of patients (Z%) reporting no negative impacts.
Interpretation:
The fixed-dose combination of latanoprost and timolol enhances treatment adherence and patient satisfaction while maintaining efficacy in lowering intraocular pressure, suggesting a need for broader adoption in clinical practice.
Limitations:
Limited studies specifically focusing on PROMs related to LTFC, which may affect the generalizability of findings.
Most studies are observational or non-randomized, which may introduce biases and affect the robustness of findings.
Conclusion:
LTFC is a beneficial treatment option for glaucoma, improving adherence and patient-reported outcomes while ensuring effective IOP control, emphasizing the importance of incorporating PROMs in treatment evaluations.
